Truncated midkine correlates with sensitivity to anticancer drugs and malignancy in human tumor cell line

Natsuyo Akuzawa1, Shigenori Nobata, Takao Shinozawa

  • 1Department of Biological and Chemical Engineering, Faculty of Engineering, Gunma University, Kiryu, Gunma, Japan.

Insights

Truncated midkine (tMK) offers cell-protective functions, suppressing apoptosis and enhancing invasion, suggesting a greater role in malignant transformation than full-length midkine (MK). This finding is crucial for improving cancer chemotherapy strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Midkine (MK) is a growth factor implicated in tumor progression and metastasis.
  • A truncated isoform of MK (tMK), lacking exon 3, has been identified.

Purpose of the Study:

  • To investigate the functional role of truncated midkine (tMK) in cancer.
  • To determine if tMK influences cancer cell survival, invasion, and malignant transformation.

Main Methods:

  • SW13 cells were transfected with human truncated MK cDNA.
  • Cells expressing tMK were treated with anticancer agents (cisplatin, etoposide, mitomycin C, paclitaxel) to induce apoptosis.
  • Cell viability and detachment on extracellular matrix were assessed.
  • Cell invasion assays were performed.

Main Results:

  • Truncated midkine (tMK) significantly suppressed apoptosis induced by anticancer agents, promoting cell viability.
  • tMK expression led to spontaneous cell detachment when cultured on extracellular matrix.
  • tMK enhanced cancer cell invasion capabilities.
  • tMK demonstrated a potentially greater role in malignant transformation compared to full-length MK.

Conclusions:

  • Truncated midkine (tMK) exhibits potent cell-protective functions, contributing to cancer cell survival.
  • tMK expression promotes key features of malignancy, including invasion and potentially enhanced transformation.
  • Assessing tMK expression may provide valuable insights for optimizing cancer chemotherapy.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...